Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Coverage Initiated at Jones Trading

Equities researchers at Jones Trading started coverage on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Jones Trading’s price objective suggests a potential upside of 155.54% from the company’s previous close.

Armata Pharmaceuticals Stock Down 7.6%

Shares of NYSEAMERICAN:ARMP opened at $5.87 on Monday. The firm has a fifty day simple moving average of $6.20 and a two-hundred day simple moving average of $4.02. Armata Pharmaceuticals has a 52 week low of $0.90 and a 52 week high of $16.34. The stock has a market capitalization of $213.73 million, a P/E ratio of -3.62 and a beta of 1.29.

Institutional Investors Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals at the end of the most recent quarter. Institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.